(-) Axovant Sciences ( AXON ), which was sinking by more than 22% after the company said its phase 2 clinical study of nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy body dementia (LBD) failed to meet the primary efficacy endpoint of reduction in frequency of RBD events as measured by sleep laboratory video assessment.
(+) Marinus Pharmaceuticals ( MRNS ) was higher by more than 8% after the biopharmaceutical company reported positive results from its phase 2 clinical trials evaluating ganaxolone intravenous and oral in women with postpartum depression.
(+) Ra Pharmaceuticals ( RARX ) was more than 7% higher as it reported that its phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG) achieved clinically meaningful and statistically significant reductions in both the primary and key secondary endpoints for both zilucoplan dose groups tested versus placebo at 12 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.
Go to Appearance > Customize > Subscribe Pop-up to set this up.
Wealth Empire Newsletter
Register now for free updates and alerts
Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.